Lexicon Pharmaceuticals Inc LXRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences
-
Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure
-
Lexicon Pharma Earns $10 Million Milestone Payment from Novo Nordisk
-
Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851
-
Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
-
Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026
-
Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM)
-
Novo Nordisk Begins Study of Lexicon Oral Obesity Drug
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 444.96M
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 15.19
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 81
- Website
- https://www.lexpharma.com
Valuation
|
Metric
|
LXRX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 4.10 |
Price/Sales | 15.19 |
Price/Cash Flow | — |
Price/Earnings
LXRX
Financial Strength
|
Metric
|
LXRX
|
|---|---|
Quick Ratio | 13.07 |
Current Ratio | 13.37 |
Interest Coverage | −7.02 |
Quick Ratio
LXRX
Profitability
|
Metric
|
LXRX
|
|---|---|
Return on Assets (Normalized) | −19.41% |
Return on Equity (Normalized) | −30.00% |
Return on Invested Capital (Normalized) | −20.31% |
Return on Assets
LXRX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|TZDP>% | LOCK|h&Wg | $127B | |||
| Moderna Inc
MRNA
| LOCK|%ll@H^! | LOCK|Yr | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|$@njT^ | LOCK|>w<#y | $81B | |||
| argenx SE ADR
ARGX
| LOCK|$<&Kt!K | LOCK|WV? | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|H%cV^V? | LOCK|nrY | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|!K>nTxZ | LOCK|X&hYK | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|t@&z>Pn | LOCK|hG>M@ | $27B | |||
| Incyte Corp
INCY
| LOCK|QtNy#^ | LOCK|g$$ | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|&%cqR&T | LOCK|>r | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|KdhH&<t | LOCK|&d | $14B |
United States